2024-02-15
The preclinical study results of IMM2902 published in "Drug Resistance Updates"
On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".
View more
2024-01-10
Dr. Tian Wenzhi, founder and chairman of ImmuneOnco to attend the 42nd J.P. Morgan Healthcare Annual Conference and deliver a speech at the Biotech Showcase™
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the founder and chairman of ImmunueOnco, Dr. Tian, Wenzhi, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024 and deliver a speech at the Biotech Showcase™ held at the same time, comprehensively demonstrate ImmuneOnco’s innovative product pipeline and progress in clinical research and development.
View more
2023-10-27
The National Medical Products Administration (NMPA) approved ImmuneOnco‘s application for IMM2510 combined with IMM27M in treatment of advanced solid tumors
On October 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that 2 drug candidates independently developed by the company, IMM2510, a bispecific antibody-receptor recombinant protein targeting PD-L1/VEGFA and IMM27M, an ADCC-enhanced CTLA-4 monoclonal antibody, are proposed to combined for the treatment of advanced solid tumors.
View more
2023-10-16
ImmuneOnco's clinical trial application for humanized antibody drug IMM47 targeting CD24 was approved by the National Medical Products Administration (NMPA)
On October 16, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the company's independently developed humanized IgG1 CD24 antibody(Project number: IMM47) was approved by the National Medical Products Administration (NMPA) for clinical trials.
View more
2023-10-04
ImmuneOnco is about to report phase II clinical data of Timdarpacept (IMM01) at the 2023 American Society of Hematology (ASH) Annual Meeting
On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.
View more
